OBJECTIVE: Our objective was to delineate the potential role of adipogenesis in insulin resistance and type 2 diabetes. Obesity is characterized by an increase in adipose tissue mass resulting from enlargement of existing fat cells (hypertrophy) and/or from increased number of adipocytes (hyperplasia). The inability of the adipose tissue to recruit new fat cells may cause ectopic fat deposition and insulin resistance. RESEARCH METHODS AND PROCEDURES: We examined the expression of candidate genes involved in adipocyte proliferation and/or differentiation [CCAAT/enhancer-binding protein (C/EBP) alpha, C/EBPdelta, GATA domain-binding protein 3 (GATA3), C/EBPbeta, peroxisome proliferator-activated receptor (PPAR) gamma2, signal transducer and activator of transcription 5A (STAT5A), Wnt-10b, tumor necrosis factor alpha, sterol regulatory element-binding protein 1c (SREBP1c), 11 beta-hydroxysteroid dehydrogenase, PPARG angiopoietin-related protein (PGAR), insulin-like growth factor 1, PPARgamma coactivator 1alpha, PPARgamma coactivator 1beta, and PPARdelta] in subcutaneous adipose tissue from 42 obese individuals with type 2 diabetes and 25 non-diabetic subjects matched for age and obesity. RESULTS: Insulin sensitivity was measured by a 3-hour 80 mU/m2 per minute hyperinsulinemic glucose clamp (100 mg/dL). As expected, subjects with type 2 diabetes had lower glucose disposal (4.9 +/- 1.9 vs. 7.5 +/- 2.8 mg/min per kilogram fat-free mass; p < 0.001) and larger fat cells (0.90 +/- 0.26 vs. 0.78 +/- 0.17 microm; p = 0.04) as compared with obese control subjects. Three genes (SREBP1c, p < 0.01; STAT5A, p = 0.02; and PPARgamma2, p = 0.02) had significantly lower expression in obese type 2 diabetics, whereas C/EBPbeta only tended to be lower (p = 0.07). DISCUSSION: This cross-sectional study supports the hypothesis that impaired expression of adipogenic genes may result in impaired adipogenesis, potentially leading to larger fat cells in subcutaneous adipose tissue and insulin resistance.
OBJECTIVE: Our objective was to delineate the potential role of adipogenesis in insulin resistance and type 2 diabetes. Obesity is characterized by an increase in adipose tissue mass resulting from enlargement of existing fat cells (hypertrophy) and/or from increased number of adipocytes (hyperplasia). The inability of the adipose tissue to recruit new fat cells may cause ectopic fat deposition and insulin resistance. RESEARCH METHODS AND PROCEDURES: We examined the expression of candidate genes involved in adipocyte proliferation and/or differentiation [CCAAT/enhancer-binding protein (C/EBP) alpha, C/EBPdelta, GATA domain-binding protein 3 (GATA3), C/EBPbeta, peroxisome proliferator-activated receptor (PPAR) gamma2, signal transducer and activator of transcription 5A (STAT5A), Wnt-10b, tumor necrosis factor alpha, sterol regulatory element-binding protein 1c (SREBP1c), 11 beta-hydroxysteroid dehydrogenase, PPARG angiopoietin-related protein (PGAR), insulin-like growth factor 1, PPARgamma coactivator 1alpha, PPARgamma coactivator 1beta, and PPARdelta] in subcutaneous adipose tissue from 42 obese individuals with type 2 diabetes and 25 non-diabetic subjects matched for age and obesity. RESULTS:Insulin sensitivity was measured by a 3-hour 80 mU/m2 per minute hyperinsulinemic glucose clamp (100 mg/dL). As expected, subjects with type 2 diabetes had lower glucose disposal (4.9 +/- 1.9 vs. 7.5 +/- 2.8 mg/min per kilogram fat-free mass; p < 0.001) and larger fat cells (0.90 +/- 0.26 vs. 0.78 +/- 0.17 microm; p = 0.04) as compared with obese control subjects. Three genes (SREBP1c, p < 0.01; STAT5A, p = 0.02; and PPARgamma2, p = 0.02) had significantly lower expression in obese type 2 diabetics, whereas C/EBPbeta only tended to be lower (p = 0.07). DISCUSSION: This cross-sectional study supports the hypothesis that impaired expression of adipogenic genes may result in impaired adipogenesis, potentially leading to larger fat cells in subcutaneous adipose tissue and insulin resistance.
Authors: M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt Journal: Diabetes Care Date: 1998-04 Impact factor: 19.112
Authors: L Fajas; K Schoonjans; L Gelman; J B Kim; J Najib; G Martin; J C Fruchart; M Briggs; B M Spiegelman; J Auwerx Journal: Mol Cell Biol Date: 1999-08 Impact factor: 4.272
Authors: Ji Young Kim; Dae Hyun Kim; Jaehun Choi; Jin-Kyu Park; Kyu-Shik Jeong; Christiaan Leeuwenburgh; Byung Pal Yu; Hae Young Chung Journal: Age (Dordr) Date: 2009-03-11
Authors: M Muniandy; S Heinonen; H Yki-Järvinen; A Hakkarainen; J Lundbom; N Lundbom; J Kaprio; A Rissanen; M Ollikainen; K H Pietiläinen Journal: Int J Obes (Lond) Date: 2017-04-25 Impact factor: 5.095
Authors: Jeanine B Albu; Leonie K Heilbronn; David E Kelley; Steven R Smith; Koichiro Azuma; Evan S Berk; F Xavier Pi-Sunyer; Eric Ravussin Journal: Diabetes Date: 2009-12-22 Impact factor: 9.461
Authors: Giulio G Muccioli; Damien Naslain; Fredrik Bäckhed; Christopher S Reigstad; Didier M Lambert; Nathalie M Delzenne; Patrice D Cani Journal: Mol Syst Biol Date: 2010-07 Impact factor: 11.429
Authors: Tamara Tchkonia; Dean E Morbeck; Thomas Von Zglinicki; Jan Van Deursen; Joseph Lustgarten; Heidi Scrable; Sundeep Khosla; Michael D Jensen; James L Kirkland Journal: Aging Cell Date: 2010-08-15 Impact factor: 9.304
Authors: S Heinonen; L Saarinen; J Naukkarinen; A Rodríguez; G Frühbeck; A Hakkarainen; J Lundbom; N Lundbom; K Vuolteenaho; E Moilanen; P Arner; S Hautaniemi; A Suomalainen; J Kaprio; A Rissanen; K H Pietiläinen Journal: Int J Obes (Lond) Date: 2014-02-19 Impact factor: 5.095